全文1236字,阅读约需4分钟,帮我划重点划重点01华领医药与拜耳终止合作,收回华堂宁在中国的商业化权益,自2025年1月1日起生效。02拜耳曾获得华堂宁在中国的独家商业化权益,支付3亿元预付款和最高可达到41.8亿元的里程碑付款。03由于华堂宁上市后的销售情况不亮眼,华领医药可能寻求其他潜在合作伙伴。04然而,拜耳方面表示,终止合作的决定是华领医药根据自身业务发展考虑,双方友好协商达成一致的。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.